| Azithromycin 3 to 5 days short‐term treatment for acute otitis media |
|
Patient or population: patients with acute otitis media
Settings:
Intervention: Azithromycin 3 to 5 days short‐term treatment |
| Outcomes |
Illustrative comparative risks* (95% CI) |
Relative effect
(95% CI) |
No of Participants
(studies) |
Quality of the evidence
(GRADE) |
Comments |
| Assumed risk |
Corresponding risk |
| Control |
Azithromycin 3 to 5 days short‐term treatment |
| Treatment failure at 1 month or less |
Study population |
OR 1.02
(0.87 to 1.2) |
4354
(19) |
|
|
| 185 per 1000 |
188 per 1000
(165 to 214) |
| Medium risk population |
| 61 per 1000 |
62 per 1000
(53 to 72) |
| Treatment failure at 8 to 19 days |
Study population |
OR 1.27
(1.04 to 1.55) |
4347
(18) |
|
|
| 95 per 1000 |
118 per 1000
(98 to 140) |
| Medium risk population |
| 56 per 1000 |
70 per 1000
(58 to 84) |
| Treatment failure at 20 to 30 days |
Study population |
OR 0.98
(0.82 to 1.17) |
2708
(11) |
|
|
| 265 per 1000 |
261 per 1000
(228 to 297) |
| Medium risk population |
| 273 per 1000 |
269 per 1000
(235 to 305) |
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio; |
| GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate. |
